AbbVie Acquires Capstan to Advance In Vivo CAR-T Therapies

Published on LinkedIn via Spencer Knight

AbbVie has announced a $2.1 billion acquisition of Capstan Therapeutics to deepen its investment in in vivo CAR‑T cell therapies. Capstan’s lead candidate CPTX2309 uses lipid nanoparticle (LNP) delivery to reprogram CD8+ T cells directly in the body, eliminating the need for ex vivo cell processing. The deal gives AbbVie access to RNA and LNP engineering platforms and aligns with its long‑term immunology strategy beyond Humira, with potential applications in lupus, MS, and other autoimmune conditions.

Read the full article on LinkedIn:

👉 AbbVie Makes $2.1B In Vivo CAR-T Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.